newsfilter
← Latest News
GlobeNewswire·

Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Advanced research and development of CUE-401 for IND (Investigational New Drug) readiness –CUE-401 is the Company's lead asset for the treatment of autoimmune and inflammatory diseasesAppointed industry veteran Lucinda